CDK6 and neoplasm: Specifically, miR-641 was identified as a tumor suppressor in NSCLC [23, 24], and researchers found that miR-641 inhibited NSCLC progression by targeting murine double minute 2 (MDM2) [24] and cyclin-dependent kinase 6 (CDK6) [23], respectively.